| P50 | author | Gareth Matthews | Q59688854 |
| P2093 | author name string | Christopher L-H Huang | |
| | Claire A Martin | |
| P2860 | cites work | MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia | Q22009462 |
| | Cardiac conduction defects associate with mutations in SCN5A | Q22010507 |
| | A cardiac arrhythmia syndrome caused by loss of ankyrin-B function | Q24295030 |
| | Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak | Q24296910 |
| | A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene | Q24297875 |
| | Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias | Q24298971 |
| | Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans | Q24608179 |
| | Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org) | Q24654954 |
| | Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death | Q24674590 |
| | Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death | Q24675134 |
| | Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia | Q28201561 |
| | Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia | Q28216442 |
| | The genetic basis of Brugada syndrome: a mutation update | Q28252115 |
| | Genetic basis and molecular mechanism for idiopathic ventricular fibrillation | Q28265902 |
| | Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death | Q28278262 |
| | Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia | Q28279395 |
| | Catecholaminergic polymorphic ventricular tachycardia | Q28287523 |
| | The mechanism of catecholaminergic polymorphic ventricular tachycardia may be triggered activity due to delayed afterdepolarization | Q28306389 |
| | Sudden death in patients and relatives with the syndrome of right bundle branch block, ST segment elevation in the precordial leads V(1)to V(3)and sudden death | Q28369489 |
| | "Brugada" syndrome: clinical data and suggested pathophysiological mechanism | Q31913453 |
| | Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts | Q33145152 |
| | Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. | Q33145274 |
| | Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. | Q33146000 |
| | Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. | Q33146452 |
| | Arrhythmias in patients with Brugada-type electrocardiographic findings | Q33146468 |
| | Natural history of Brugada syndrome: insights for risk stratification and management | Q33147491 |
| | Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. | Q33147854 |
| | Electrophysiologic investigation in Brugada syndrome; yield of programmed ventricular stimulation at two ventricular sites with up to three premature beats. | Q33148051 |
| | Proposed diagnostic criteria for the Brugada syndrome: consensus report | Q33148286 |
| | Implantable cardioverter defibrillator in high-risk long QT syndrome patients | Q33148945 |
| | Short QT Syndrome: a familial cause of sudden death | Q33149259 |
| | Efficacy of quinidine in high-risk patients with Brugada syndrome | Q33151791 |
| | Mouse models of long QT syndrome | Q33154363 |
| | Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study | Q33154495 |
| | Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia | Q33155477 |
| | Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome | Q33156201 |
| | Sudden cardiac arrest associated with early repolarization | Q33156255 |
| | Mode of onset of ventricular fibrillation in patients with early repolarization pattern vs. Brugada syndrome | Q33158008 |
| | Idiopathic ventricular fibrillation | Q33160592 |
| | Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients | Q33173888 |
| | Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome | Q33174622 |
| | Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. | Q33175786 |
| | Early repolarization | Q33539317 |
| | Ion channels and ventricular arrhythmias: cellular and ionic mechanisms underlying the Brugada syndrome | Q33652599 |
| | The syndrome of right bundle branch block ST segment elevation in V1 to V3 and sudden death--the Brugada syndrome | Q33935865 |
| | Ventricular fibrillation with prominent early repolarization associated with a rare variant of KCNJ8/KATP channel | Q34015485 |
| | Long-term outcome associated with early repolarization on electrocardiography | Q34020187 |
| | Sudden death associated with short-QT syndrome linked to mutations in HERG. | Q34283788 |
| | Short QT syndrome: pharmacological treatment | Q34314532 |
| | Diagnostic criteria for the long QT syndrome. An update | Q34351752 |
| | Cellular basis for the electrocardiographic J wave | Q34370136 |
| | Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. | Q34385271 |
| | Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. | Q34395488 |
| | Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium | Q34395514 |
| | Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry | Q34422572 |
| | Brugada syndrome: from cell to bedside | Q34667046 |
| | Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation | Q34785746 |
| | Sodium channels as macromolecular complexes: implications for inherited arrhythmia syndromes | Q36140857 |
| | Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3. | Q39722604 |
| | Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current | Q41256047 |
| | Structure of a complex between a voltage-gated calcium channel beta-subunit and an alpha-subunit domain. | Q41858723 |
| | Increased right ventricular repolarization gradients promote arrhythmogenesis in a murine model of Brugada syndrome | Q42026470 |
| | Distribution, splicing and glucocorticoid-induced expression of cardiac alpha 1C and alpha 1D voltage-gated Ca2+ channel mRNAs | Q42448384 |
| | The pause that refreshes, or does it? Mechanisms in torsades de pointes | Q43037537 |
| | Regional variations in action potential alternans in isolated murine Scn5a (+/-) hearts during dynamic pacing | Q43102967 |
| | Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. | Q43266239 |
| | Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome | Q44648714 |
| | Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations | Q45273441 |
| | The prevalence of Brugada ECG in adult patients in a large university hospital in the western United States | Q46174920 |
| | Mutation in the KCNQ1 gene leading to the short QT-interval syndrome | Q47438291 |
| | Clinical course and risk stratification of patients affected with the Jervell and Lange-Nielsen syndrome. | Q51145417 |
| | Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. | Q51955831 |
| | Long QT syndrome. | Q53213950 |
| | Exercise-induced ECG changes in Brugada syndrome. | Q54458188 |
| | A novel early onset lethal form of catecholaminergic polymorphic ventricular tachycardia maps to chromosome 7p14-p22 | Q55843608 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 84-94 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Postgraduate Medicine | Q7234297 |
| P1476 | title | Recent developments in the management of patients at risk for sudden cardiac death | |
| P478 | volume | 123 | |